SG11201810048VA - Tri-segmented pichinde viruses as vaccine vectors - Google Patents

Tri-segmented pichinde viruses as vaccine vectors

Info

Publication number
SG11201810048VA
SG11201810048VA SG11201810048VA SG11201810048VA SG11201810048VA SG 11201810048V A SG11201810048V A SG 11201810048VA SG 11201810048V A SG11201810048V A SG 11201810048VA SG 11201810048V A SG11201810048V A SG 11201810048VA SG 11201810048V A SG11201810048V A SG 11201810048VA
Authority
SG
Singapore
Prior art keywords
international
pichinde
segment
pct
orf
Prior art date
Application number
SG11201810048VA
Inventor
Weldi Bonilla
Daniel David Pinschewer
Klaus Orlinger
Original Assignee
Univ Basel
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel, Hookipa Biotech Gmbh filed Critical Univ Basel
Publication of SG11201810048VA publication Critical patent/SG11201810048VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 11 11111111111111 0101110111011111111110111111011110111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/198726 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: C12N 15/86 (2006.01) CO7K 14/005 (2006.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/EP2017/061865 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) — 17 May 2017 (17.05.2017) with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/338,400 18 May 2016 (18.05.2016) US (71) Applicants: HOOKIPA BIOTECH AG [AT/AT]; Helmut-Qualtinger-Gasse 2, 1030 Wien (AT). UNIVERSITAT BASEL [CH/CH]; Vizerektorat Forschung, Petersgraben 35, 4001 Basel (CH). (72) Inventors: BONILLA, Weldi; Im Zehntenfrei 5, 4102 Bin- ningen (CH). PINSCHEWER, Daniel David; Im Zehnten- _ frei 5, 4102 Binningen (CH). ORLINGER, Klaus; Schatz- gasse 4/1, 1190 Wien (AT). — = (74) Agent: JONES DAY (ASSOCIATION NO. 215); PrinzregentenstraBe 11, 80538 Mfinchen (DE). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (81) — — = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = Designated States (unless otherwise indicated, for every (84) _ _ kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = 1-1 ei IN (54) Title: TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS GC 0\ (57) : The present application relates to Pichinde viruses with rearrangements of their open reading frames (\"ORF\") in their 1-1 ---- genomes. In particular, described herein is a modified Pichinde virus genomic segment, wherein the Pichinde virus genomic segment IN IN is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented © Pichinde virus particles comprising one L segment and two S segments or two L segments and one S segment. The Pichinde virus, N described herein may be suitable for vaccines and/or treatment of diseases and/or for the use in immunotherapies. C
SG11201810048VA 2016-05-18 2017-05-17 Tri-segmented pichinde viruses as vaccine vectors SG11201810048VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338400P 2016-05-18 2016-05-18
PCT/EP2017/061865 WO2017198726A1 (en) 2016-05-18 2017-05-17 Tri-segmented pichinde viruses as vaccine vectors

Publications (1)

Publication Number Publication Date
SG11201810048VA true SG11201810048VA (en) 2018-12-28

Family

ID=58800799

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810048VA SG11201810048VA (en) 2016-05-18 2017-05-17 Tri-segmented pichinde viruses as vaccine vectors

Country Status (13)

Country Link
US (2) US20190135875A1 (en)
EP (1) EP3458593A1 (en)
JP (2) JP7254018B2 (en)
KR (1) KR20190016032A (en)
CN (2) CN117486979A (en)
AU (2) AU2017266738B2 (en)
BR (1) BR112018073794A2 (en)
CA (1) CA3023599A1 (en)
EA (1) EA201892648A1 (en)
IL (1) IL262963A (en)
MX (1) MX2018013956A (en)
SG (1) SG11201810048VA (en)
WO (1) WO2017198726A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009083210A1 (en) 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors
EP3904522A1 (en) 2013-12-03 2021-11-03 Hookipa Biotech GmbH Cmv vaccines
EP3218504B1 (en) 2014-11-13 2020-07-22 Université de Genève Tri-segmented arenaviruses as vaccine vectors
CA2987155A1 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
SI3371316T1 (en) 2015-11-04 2023-02-28 Hookipa Biotech Gmbh Vaccines against hepatitis b virus
PT3373959T (en) 2015-11-12 2022-08-09 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
CA3058539A1 (en) 2017-04-07 2018-10-11 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
MX2021015452A (en) 2019-06-25 2022-02-11 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use.
CN114761041A (en) 2019-07-16 2022-07-15 吉利德科学公司 HIV vaccines and methods of making and using the same
CA3149557A1 (en) 2019-09-30 2021-04-08 Scott J. Balsitis Hbv vaccines and methods treating hbv
EP4055173A1 (en) 2019-11-07 2022-09-14 Universität Basel Vizerektorat Forschung Arenaviruses as vectors
CN116057068A (en) 2019-12-06 2023-05-02 精密生物科学公司 Optimized engineered meganucleases with specificity for recognition sequences in hepatitis b virus genomes
CR20220303A (en) 2019-12-24 2022-09-02 Gilead Sciences Inc Diacylglycerol kinase modulating compounds
TW202200161A (en) 2020-03-20 2022-01-01 美商基利科學股份有限公司 Prodrugs of 4’-c-substituted-2-halo-2’-deoxyadenosine nucleosides and methods of making and using the same
US20230346906A1 (en) 2020-05-29 2023-11-02 Hookipa Biotech Gmbh Cancer treatment strategies using arenavirus vectors
JP2024512566A (en) 2021-03-23 2024-03-19 ホオキパ バイオテック ジーエムビーエイチ Arenavirus used to treat prostate cancer
WO2022238546A1 (en) 2021-05-13 2022-11-17 Hookipa Biotech Gmbh Arenaviruses as vectors
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022269362A2 (en) * 2021-06-21 2022-12-29 Vaxxinova International B.V. Veterinary viral vector
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023079153A1 (en) * 2021-11-08 2023-05-11 Hookipa Biotech Gmbh Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2536426T3 (en) 2006-03-23 2015-05-25 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
ES2388556T3 (en) 2006-03-23 2012-10-16 Novartis Ag Immunopotentiating compounds
WO2009083210A1 (en) * 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors
US9809801B2 (en) * 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
CN103224999B (en) * 2013-04-25 2015-11-18 中华人民共和国大榭出入境检验检疫局 Detect degenerated primer and the RT-PCR detection method of arenavirus coe virus
CA2961913A1 (en) * 2014-09-22 2016-03-31 Regents Of The University Of Minnesota Pichinde virus reverse genetics system and methods of use

Also Published As

Publication number Publication date
MX2018013956A (en) 2019-07-04
US20190135875A1 (en) 2019-05-09
KR20190016032A (en) 2019-02-15
JP2019516410A (en) 2019-06-20
CN109804074B (en) 2023-10-10
JP7254018B2 (en) 2023-04-07
EP3458593A1 (en) 2019-03-27
AU2017266738A1 (en) 2018-11-29
WO2017198726A1 (en) 2017-11-23
JP2023012463A (en) 2023-01-25
AU2023285703A1 (en) 2024-01-18
CN109804074A (en) 2019-05-24
US20220289797A1 (en) 2022-09-15
AU2017266738B2 (en) 2023-10-12
CA3023599A1 (en) 2017-11-23
CN117486979A (en) 2024-02-02
EA201892648A1 (en) 2019-06-28
BR112018073794A2 (en) 2019-02-26
IL262963A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201808751SA (en) T cell receptors
SG11201808709VA (en) T cell receptors
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201808750PA (en) T cell receptors
SG11201805229YA (en) Means and methods for treating hbv
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201808990QA (en) Compositions for topical application of compounds
SG11201807912SA (en) Vaccine against rsv
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201805001UA (en) Method of treating influenza a
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201903042VA (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201809993VA (en) Oncolytic viruses comprising esrage and methods of treating cancer
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201803918VA (en) Production of steviol glycosides in recombinant hosts